(Total Views: 328)
Posted On: 02/11/2019 9:19:21 PM
Post# of 72446
Another good Kevetrin comparison from a couple months ago. This was a cash starved company too.
https://seekingalpha.com/article/4230252-agen...d-sciences
Agenus received $120 million upfront + $30 million equity investment with $1.7 billion in fees and milestones for three preclinical I/O targets with an option for two more.
Ignore the fact that Kevetrin did a phase 1 and a tiny phase 2. Divide those numbers by 3 if you want to place Kevetrin on equal footing to the I/O targets. That's $40 million upfront with $565 million in milestones.
Plenty of value in Kevetrin as-is.
https://seekingalpha.com/article/4230252-agen...d-sciences
Agenus received $120 million upfront + $30 million equity investment with $1.7 billion in fees and milestones for three preclinical I/O targets with an option for two more.
Ignore the fact that Kevetrin did a phase 1 and a tiny phase 2. Divide those numbers by 3 if you want to place Kevetrin on equal footing to the I/O targets. That's $40 million upfront with $565 million in milestones.
Plenty of value in Kevetrin as-is.
(1)
(0)
